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Abstract 
	  
Small molecules identified through high-throughput screens are essential elements in 
pharmaceutical discovery programs.  It is now recognized that a substantial fraction of small 
molecules exhibit aggregating behavior leading to false positive results in many screening 
assays, typically due to nonspecific attachment to target proteins.  Therefore, the ability to 
efficiently identify compounds within a screening library that aggregate can streamline the 
screening process by eliminating unsuitable molecules from further consideration.  In this work 
we show that photonic crystal (PC) optical biosensor microplate technology can be utilized to 
identify and quantify small molecule aggregation. A group of aggregators and nonaggregators 
were tested using the PC technology, and measurements were compared with those gathered 
by three alternative methods: dynamic light scattering (DLS), an α-chymotrypsin colorimetric 
assay, and scanning electron microscopy (SEM).  The PC biosensor measurements of 
aggregation were confirmed by visual observation using SEM, and were in general agreement 
with the a-chymotrypsin assay.  DLS measurements, in contrast, demonstrated inconsistent 
readings for many compounds that are found to form aggregates in shapes very different from 
the classical spherical particles assumed in DLS modeling.  As a label-free detection method, 
the PC biosensor aggregation assay is simple to implement and provides a quantitative direct 
measurement of the mass density of material adsorbed to the transducer surface, while the 
microplate-based sensor format enables compatibility with high-throughput automated liquid 
handling methods used in pharmaceutical screening. 
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Chapter 1: Introduction 
1.1 – Pharmaceutical Drug Discovery – Natural and Synthetic Product Isolation 
Pharmaceutical drug discovery programs employ a wide variety of high-throughput 
screening (HTS) methods to identify lead compounds for further development [1-6]. These 
strategies generally include the isolation and categorization of a broad source of potential drugs 
or drug-like compounds prior to the screening and evaluation of these compounds over an 
extended research and development cycle (Fig. 1)[7]. Two primary isolation strategies include 
extraction from natural products and combinatorial chemistry approaches designed around a 
specific compound. These approaches are often used in tandem with one another – once a 
specific natural product is found, combinatorial chemistry can often be used to enhance its 
functionality and therefore optimizing its utility as a pharmaceutical solution. Compounds 
created from hybridization of these two strategies are known as semi-synthetic compounds or 
derivatives. 
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Figure 1: Process schematic for drug discovery. High-throughput screening of naturally-occurring 
organic compounds remains the most productive method through which to seek novel therapeutics. 
Despite recent advances in compound synthesis and isolation, however, it remains a complex 
process, often requiring over a decade for a particular compound to progress from an initial screen to a 
clinical use. Shortening the time invested in any of the steps highlighted above would result in a 
significant reduction in time-to-market for a particular drug (Adopted from [7]). 
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These semi-synthetic compounds possess a storied history in the pursuit of therapeutic 
compounds, and continue to be a valuable source for new studies. Supporting this assertion, 
over 60% of currently approved drugs are naturally occurring substances [8, 9]. There are three 
primary sources of new compounds in the high-throughput pharmaceutical screening arena: 
natural products, semi-synthetic derivatives of natural products, and synthetic compounds 
produced using combinatorial chemistry techniques on natural product models [8, 9, 10]. Basing 
the search for novel inhibitors on novel compounds is not only a choice of convenience, 
however. Interesting relationships between naturally occurring compounds and their cognate 
receptors can be related to the evolution of processes deeply ingrained in cell biology – 
processes that have since been modified to present functionalities that remain incredibly 
disparate between the organism producing the natural compound and the organism expressing 
a target suitable for therapeutic intervention. 
 While naturally occurring compounds have made great contributions to the state of 
modern pharmacology, recent advances in combinatorial chemistry have allowed the synthesis 
of derivative compounds and original compounds with unprecedented efficiency. The resulting 
compounds present a unique challenge, however, in that they lack the heterogeneity typical of 
natural products with respect to several qualities desirable for effective drug design. Molecular 
characteristics including chirality, asymmetry, and charge distribution are critical to the 
functionality of many currently used drugs [9, 10].  The rapid availability of derivatives increased 
by combinatorial chemistry has been faulted for this lack of heterogeneity, as these qualities in 
particular are able to modify efficacy and specificity by orders of magnitude [9] In short, 
pharmaceutical screening campaigns remain indebted to continued extraction, isolation, and 
characterization of natural products from novel sources – a pursuit widely acknowledged as 
lengthy, expensive, and difficult [11, 12, 13]. 
Using these techniques, it is possible to compose a diverse pharmaceutical screening 
library. Typical libraries involve the use of many thousands of compounds, possessing a 
significant degree of heterogeneity with regard to the characteristics mentioned above. The 
compounds documented in this manuscript originated from the High-Throughput Screening 
Facility at the University of Illinois at Urbana-Champaign, which maintains a library containing 
over 180,000 compounds chosen using over sixty computational methods at Chembridge (San 
Diego, CA) to ensure structural heterogeneity and optimal similarity to effective drugs (Figure 2). 
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After compiling a diverse library of pharmaceutical screening candidates, the traditional 
approach calls for an application-specific screening experiment, of which there are three main 
classes. One type of screen relies on the construction of a colorimetric readout for synthesis of a 
desired reaction product – examples of such reactions are discussed in the Current Detection 
Methods section. Some screening experiments are designed around modifying cell viability – as 
such, these experiments are typically analyzed by culturing small quantities of the cells of 
interest before conducting a high-throughput reading step in context with potential 
pharmaceuticals at physiologically relevant concentrations. High-throughput reading assays for 
these experiments include flow cytometry (fluorescence-activated cell sorting, FACS), apoptosis 
detection assays (fluorescence-based and colorimetric), and live-dead cell sorting assays. This 
collection of assays provides excellent information with regard to the library compoundsʼ 
effectiveness toward a single application, but little in terms of information that may be applied 
broadly and across multiple screening campaigns.  
Such broadly applicable information has traditionally been limited to such physical 
constants as hydrophobicity, molecular weight, density, solubility, and charge, but these 
qualities have yielded little in the way of predicting a moleculeʼs success or failure for a 
particular pharmaceutical application. Recent studies have revealed some traits that are broadly 
undesirable among drug candidate, and the possibility of computational methods to predict 
problematic candidates is currently under investigation. The pharmaceutical industry, however, 
continues to rely on evidence discovered from in vitro experimentation with compound libraries 
in order to decide which compounds should be discounted from consideration and which 
compounds merit further study and optimization. 
While the current strategies have proven successful for certain problems, drug discovery 
remains a challenging and costly process. Screening campaigns often take over a decade and 
hundreds of millions of dollars to complete – as compounds progress through the screening 
process, the assays used to test their validity increase in length, complexity, and cost [12, 13]. 
For these reasons, optimizing the efficiency of drug discovery remains challenging, yet 
worthwhile objective. In this vein, the development of a broadly applicable screen to remove 
undesirable drug candidates at the earliest opportunity would affect the pharmaceutical industry 
favorably. 
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1.2 – Small Molecule Aggregators and Promiscuous Inhibition 
Throughout a screening campaign, candidates are removed for a number of faults 
causing incompatibility or reducing compoundsʼ suitability for biological use. One issue 
prominent among such screening efforts is the formation of multimeric aggregates by candidate 
compounds. Such aggregates are known to result in nonspecific interactions with many proteins 
[1, 15-19], leading to unreliable outputs from several types of screening assays [7, 13]. 
Compounds that can form large aggregates and inhibit the interactions with the target protein 
are often referred to as “promiscuous inhibitors” due to their ability to alter the function of many 
different proteins in a nonspecific manner [1, 19, 20]. In screens that measure inhibitory activity, 
such compounds are a primary source of false positive hits that must subsequently be identified 
by lower throughput secondary screening methods (Figure 2); recent studies have also shown 
that in some cases aggregation can lead to non-specific enzymatic activation [21].   
Figure 2: Small molecule aggregation as a mechanism for promiscuous inhibition. Aggregation of 
prospective drug candidate molecules can result in sequestration of the enzyme and/or substrate, 
inhibiting product formation and preventing enzyme molecules from performing their desired function. 
Because this mechanism of inhibition remains nonspecific, broad classes of enzymes remain affected, 
thereby reducing the candidate moleculeʼs utility as a specific, well-controlled inhibitor of a particular target 
reaction. 
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Previous studies have shown that high percentages (21-36%) of small molecule library 
members can form aggregates at screening concentrations, thereby overwhelming valid hits 
from the screen and drastically affecting the hit rate from HTS assays [3]. Therefore, HTS 
methods can be improved if aggregating compounds in a given library can be identified, 
characterized, and eliminated before screening is performed [1-3, 15, 18].  Although recent 
studies have shown that addition of detergent to assay buffers can minimize the aggregating 
effects of certain small molecules, high detergent concentration can also have deleterious 
effects upon the biomolecular interactions being studied, with such effects varying from 
compound to compound [1-3].  Additionally, detergent adds several layers of complexity to the 
investigation of such interactions, as the sequestration of small molecule aggregates within 
detergent micelles is subject to increasingly elusive and more complex kinetics than is the 
specific activity of the small molecules. 
 
1.3 – Current Detection Methods for Small Molecule Aggregation 
Dynamic Light Scattering (DLS) Spectroscopy	  
 There are currently several detection methods used to quantitatively measure small 
molecule aggregation.  One of the most common methods, dynamic light scattering (DLS), is 
used to quantify the size of small molecules aggregates by measuring the time-dependent 
fluctuation of scattering intensity of a coherent light source illuminating particles suspended in 
solution [1, 3, 18].  DLS relies on two fundamental assumptions in the computation of particle 
size – the first is that the particles of interest are subject to Brownian motion. The second 
assumption is that the particles are uniform in size, distribution, and composition [22]. Briefly, 
coherent light scattered from two or more particles constructively or destructively interferes at 
the detector. By calculating the autocorrelation function of the light intensity, it is possible to 
determine the time scale along which particular motion occurs within the sample. This 
information, in combination with the assumption of uniform particle size and distribution, is 
sufficient to estimate the particleʼs hydrodynamic diameter.  
 
6	  
 While DLS serves as an effective tool when these assertions remain true, small molecule 
aggregates can form in many shapes, including irregular non-uniform clumps, thin sheets, and 
fibrous tendrils [1-3, 19, 23-25]. As a result, the fidelity of DLS can be compromised when used 
for characterizing such compounds, resulting in increased error of the particle-sizing algorithm. 
Additionally, due to the complexity of the instrumentation necessary to perform DLS 
spectroscopy as well as the time needed to perform the assay, multiplexing of this assay is 
compromised. Finally, samples must often be manipulated to approximate a uniform distribution 
– thorough mixing immediately before reading is necessary for reliable results, resulting in a 
further increase in the time necessary to perform such a screen, as well as an additional source 
of error. Though DLS can be effective on small scales if experimental conditions are managed 
well, small molecule aggregators have been shown to present several complications for which 
this technique remains poorly suited, especially in the context of high-throughput screening. 
Enzyme Inhibition Assays	  
Other common methods for identification of aggregating compounds include enzyme-
based inhibition assays. These assays typically rely on the enzyme-catalyzed formation of a 
colored product, producing a detectable colorimetric change in solution. To increase throughput, 
Figure 3: Dynamic Light Scattering instrumentation. Dynamic light scattering uses a focused,  
coherent light source to illuminate the sample of interest. Scattered light is captured by the detector, 
and the intensity is recorded as a function of time to compute the autocorrelation function for each 
sample. This information can then be used to calculate the particlesʼ perceived hydrodynamic 
diameter. The DLS particle sizing model relies on Mie theory scattering, which assumes both a uniform 
particle distribution as well as uniformly spherical particles. 
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it is possible to multiplex the assay, using a plate reader to measure the absorbance of reaction 
product over a range of concentrations in context with several drug candidates simultaneously. 
Enzymes typically used for these reactions include AmpC β-lactamase, α-chymotrypsin, or 
dihydrofolate reductase [1, 19, 26]. Bacterial expression vectors are used to provide a plentiful 
source of the protein before it is purified via affinity chromatography. The chosen enzyme is then 
mixed with a specially altered substrate that produces a colored reaction product upon 
completion of the reaction. α-chymotrypsin, for example, proteolytically cleaves the carboxy-
terminal bond of glycine, tyrosine, phenylalanine, leucine, and methionine. When this reaction is 
conducted with N-acetyl-L-phenylalanine p-nitrophenyl amide, the enzyme-substrate complex 
forms the yellow intermediate, p-nitrophenolate. The concentration of this intermediate can be 
determined by measuring the absorbance of the reaction mixture at 410 nm, and comparing the 
absorbance to a range of absorbance readings for a positive control dilution series. Comparing 
reaction progress over a range of concentrations allows calculation of the reaction rate. When 
aggregation and non-specific enzyme inhibition occur, the reaction rate is altered and a change 
in kinetics can be observed. To conclusively establish nonspecific inhibition, it is common to use 
one or more of these assays  - molecules found to be promiscuous inhibitors can then be 
removed from further consideration as drug candidates.  
Figure 4: Enzyme inhibition assays. The α-chymotrypsin enzymatic inhibition assay depends on the 
use of a substrate specially designed for colorimetric detection as the reaction progresses. When N-
acetyl-L-phenylalanine p-nitrophenyl amide is cleaved by α-chymotrypsin, forming p-nitrophenolate and 
a substituted phenylalanine. The product p-nitrophenolate absorbs light at 410nm, and so can be 
detected using a spectrometer. This assay can be performed in context with drug candidates to assess 
their predilection toward nonspecific inhibition via mechanisms including small molecule aggregation. 
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Unfortunately, small molecules with significant absorbance in the range of the enzyme-
substrate intermediate can affect the absorbance output signal without respect for their potential 
for aggregation. Because the readout is not a direct product of small molecule aggregation, but 
rather an indirect measure of the compoundsʼ effects on apparently unrelated enzymatic 
reactions, It is possible to avoid conflicts using several such reactions to study each compound 
of interest, but additional screens increase the time and cost of effectively ruling out 
promiscuous inhibitors. For these reasons, a screen directly relating the properties of the 
compounds of interest would be a welcome addition to screening methods designed to detect 
aggregating small molecules. 
Surface Plasmon Resonance	  
Direct detection of small molecule aggregation on an optical biosensor surface has been 
demonstrated using surface plasmon resonance (SPR), in which the kinetic reaction rates of 
target protein interaction with small molecules are observed and used to differentiate between 
compound/target affinity binding and compound aggregation [15]. SPR is a more reliable 
method than either DLS or enzymatic inhibition as it directly quantifies the affinities of the 
molecules observed. Briefly, SPR optical sensors are made up of an optical system, a 
transducing medium relating the optical domain to the chemical/sensing region, and an 
electronic system to support the sensor and to allow data processing, collection, and analysis. 
The transducing medium transforms changes that take place in the sensing region into changes 
in refractive index. The optical part of the sensor contains a source of illumination and an optical 
structure in which surface plasmon waves are excited and interrogated. During interrogation, the 
sensor generates an electronic signal to be processed by the electronic system. To interrogate 
the sensor, light is directed via a waveguide into a metal layer built into the sensor and 
interacting directly with the analyte. Changes in the analyte alter the refractive index within the 
sensing region, causing a change in the sensor response. 
Commonly used approaches for detecting SPR signal include measurement of the 
optical wave intensity near the resonant condition and measurement of the resonant condition 
using either angular or wavelength-based interrogation techniques [27-30] (Figure 5). For 
aggregate screening, SPR instrumentation can be constructed using a flow cell through which 
drug candidates are pumped across a sensor functionalized with protein. In the event that a 
small molecule is prone to nonspecific aggregation on the sensor, the signals for a range of 
concentration can be used to characterize its nature and kinetics. SPR has been used to 
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categorize such aggregation as nonspecific, promiscuous, super-stoichiometric, or detergent-
sensitive, among other qualities [31].	   
 
 
While SPR remains useful for such categorization of drug candidates, its utility is 
compromised by its reliance on a serial flow cell-implementation. In addition to severely limiting 
throughput, the serial flow-cell format is subject to the accumulation of larger aggregating 
molecules. Sufficient removal is often impossible, necessitating the costly replacement of the 
chip to achieve true reproducibility [15, 32-34]. The increased cost and decreased throughput of 
SPR for detection of small molecule aggregation therefore present challenges that may be 
addressed with alternative optical biosensor instrumentation. 
 
Figure 5: Surface Plasmon Resonance instrumentation. SPR instrumentation has been successfully 
implemented in several varieties; three popular variations are depicted here. Prism-coupled SPR uses a 
prism-coupled instrumentation analogous to that used in Total Internal Reflection Fluorescence (TIRF) 
microscopy (a), while adequate sensitivity has been demonstrated using grating-coupled instruments as 
well (b). Finally, waveguide-coupled systems have also been used for biomolecular detection (c)[30]. 
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1.4 – Photonic Crystal Biosensors 
 In this work, we demonstrate the use of photonic crystal (PC) biosensor microplates as a 
label-free detection method for quantifying small molecule aggregation in a high-throughput 
fashion.  PC biosensors have been demonstrated as a highly sensitive method for performing a 
wide variety of biochemical and cell-based assays, with a mass density sensitivity resolution 
less than 0.1 pg/mm2 and a large dynamic range [35-36].  As described in previous publications, 
the PC biosensor is comprised of a subwavelength periodic surface structure that resonantly 
reflects a narrow band of wavelengths when illuminated with a broadband collimated light 
source [20-22].  The wavelength reflected from the PC surface is modulated by changes in the 
refractive index of material within an evanescent field region that extends approximately 300-
500 nm from the PC surface into the adjacent liquid media.   
 Briefly, the sensors are composed of a low refractive index UV-curable polymer (UVCP) 
molded into a diffraction grating with a 550 nm period and a 200 nm grating depth. This 
diffraction grating is constructed by pouring the liquid UVCP into a Si master wafer patterned 
with the desired diffraction grating, and covering the UVCP with a clear PET substrate. After 
curing the UVCP and removing the Si master, the result is a UVCP diffraction grating attached 
directly to PET. The grating can then be coated with highly reflective TiO2, which results in the 
rejection of light at the resonant wavelength of the sensor. The dimensions specified above, 
combined with an aqueous medium, allow for a resonant wavelength in the near-IR range. This 
allows for decreased interference from visible light, and can be monitored with a near-IR 
spectrometer. Because the sensor and PET substrate are flexible and easily manufactured, they 
can be fitted to multiwell plates to ease multiplexing, and can be used in conjunction with high-
throughput liquid handling systems to further improve throughput. This instrumentation is 
commercially available in the form of the BINDTM Reader detection instrument (SRU Biosystems, 
Woburn MA, USA), which was used for the work described here. 
The detection instrument illuminates the PC microplate from below with a broadband 
light source, and uses a spectrometer to measure the peak wavelength value (PWV) of the 
resonantly reflected light.  As biomolecular binding occurs within an evanescent field region, the 
effective refractive index of the corresponding sensor region is increased. Measuring the PWV 
before and after addition of the biomolecules allows the calculation of a PWV shift as a result of 
biomolecule adsorption. The BIND Reader is configured for high-throughput screening, as it is 
able to gather kinetic data for entire multiwall plates, including 96, 384, and 1536-well plate 
formats. To do so, the instrument incorporates 8 multiplexed illumination/detection reading 
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heads, for gathering measurements from 8 biosensor regions in parallel, and is capable of 
scanning an entire 384-well microplate in approximately 20 s.  The scanning may be repeated to 
gather kinetic binding information for further characterization of biomolecular binding[22, 23]. 
 
 
Figure 6: Photonic crystal biosensor instrumentation. The photonic crystal biosensor is 
illuminated with collimated, broadband white light from an LED source via a fiberoptic probe. The 
resonant reflected wavelength for each point on the sensor is then relayed through a fiberoptic probe 
and to a spectrometer that records the peak wavelength value (PWV). When readings are taken 
before and after addition of biomolecules, it is possible to equate shifts in the PWV for a particular 
plate well with addition of a particular biomolecule. If the added molecules are drug candidates in the 
absence of a binding partner, increased PWV shifts are indicative of aggregation, or promiscuous 
inhibition, therefore negating choice of the compounds for further consideration for pharmaceutical 
screening [26]. 
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While the BIND system fills the need for high-throughput screening, an alternative 
imaging method can be used to verify the uniformity of PWV shift across the sensing region. 
Two types of detection instruments for PC biosensors are used in this work. A second 
instrument, the BIND Scanner, SRU Biosystems uses free space optics to illuminate the sensor 
and an imaging spectrometer to produce measurements of the spatial distribution of PWV 
across the PC surface with a resolution of ~22.3x22.3 µm2/pixel [37-38].	   
 
Though photonic crystal biosensors have not previously been used for characterization 
of small molecule aggregation, their utility has been successfully demonstrated in the 
pharmaceutical screening arena. Because the sensors can be manufactured with relative ease 
and at a cost amenable to large-scale screening, PC biosensor-based detection of aggregation 
is a viable solution for several problems currently restricting the efficiency of pharmaceutical 
screening campaigns. As the PC detection mechanism relies directly on the properties of the 
Figure 7: BIND imaging instrument. To verify that PWV shift occurs across the entire PC biosensor 
surface and is not merely constricted to the center of each well, the BIND imaging instrument can be 
used. Replacing the fiberoptic detection probes with a beam-splitter and an imaging spectrometer, it is 
possible to calculate PWV for discrete areas of the sensor, at a pixel resolution of 22.3x22.3µm2 [36]. 
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analytes and not on the detection of an intermediate or reaction product, it results in the direct 
detection of aggregation. This further reduces costs by restricting the quantities and types of 
reagents necessary for involved assays including enzyme kinetic assays. The work documented 
here is aimed to provide detailed characterization of the use and suitability of PC biosensor-
based detection of small molecule aggregation, and therefore, small molecule aggregation. 
In the course of applying recently developed PC biosensor technology for the detection 
of inhibitors of protein—DNA interactions, we noted several compounds in our compound 
collection that gave substantially larger shifts in the reflected wavelength signals than could be 
explained solely by stoichiometric binding of the molecule to the immobilized target [39]. To 
study these phenomena in greater detail, we selected a group of 22 compounds including 
known aggregators, known nonaggregators, and previously uncharacterized compounds that 
were suspected of aggregation.  These compounds were purposefully selected to have a wide 
range of molecular weights while possessing core structural similarities to demonstrate the 
variety with which aggregation can occur, and the robust nature of the PC detection system. The 
results of comparison experiments between PC biosensor aggregation measurements (collected 
in a 384-well microplate format) and measurements obtained by DLS, enzyme-based inhibition 
assays, and physical observation using scanning electron microscopy (SEM) are reported 
herein. 
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Chapter 2: Materials and Methods 
2.1 – Small Molecule Library and Compound Selection 
A set of 20 small molecules was selected from an in-house library kept at the University 
of Illinois at Urbana-Champaign High-Throughput Screening Facility [39-41]. Molecules were 
maintained as 10mM stock solutions in DMSO. The control molecules biotin and congo red (CR) 
were also maintained in 10mM stock solutions in DMSO to maintain uniformity between control 
molecules and library compounds. Congo Red (CR) was purchased from the Agfa-Gevaert 
Group (AGFA, Mortsel, BEL).  Biotin, dimethylsulfoxide (DMSO), phosphate-buffered saline 
(PBS) solution, and Tween-20 were purchased from Sigma-Aldrich Co. (St. Louis, MO USA) 
Triton X-100 was purchased from Union Carbide Corporation (Houston, TX USA). All 
compounds were maintained at -20°C for long-term storage before being transferred to 4°C for 
the course of experimentation over a period of several weeks. All compounds were allowed to 
progress to room temperature to ensure proper thawing of DMSO prior to experimentation. 
Molecules were chosen to possess a variety of molecular weights and functional groups 
while demonstrating several similarities in core structure. The compounds have similar core 
characteristics in the presence of one or more aromatic rings, as well as the presence of several 
electron-withdrawing groups (EWGs). These characteristics are common among commercially 
used drugs, as the modification or substitution of particular functional groups can profoundly 
affect the binding characteristics and inhibitory profiles of the pharmaceuticals, with potentially 
beneficial or disadvantageous consequences. The selected compounds have a broad range of 
molecular weights, from 170.1 g/mol to 696.7 g/mol, demonstrating a range typical of 
commercially available drugs. 
Finally, hydrophobicity is an important consideration in the selection of drug candidate 
compounds, as solubility and permeability vary as a product of the factors listed above. To 
ensure assay robustness against this variable, the compounds selected were designed to cover 
a range of hydrophobicity, ensuring that the proposed screening methodology is not biased 
toward a particular class of small molecules. For a consistent estimate of hydrophobicity, 
ChemDraw software was used to calculate relative hydrophobicity in the form of the ClogP 
calculation, where CLogP = log([compound in octanol]/[compound in water]) in a 1:1 mixture of 
water and octanol. CLogP values for the library compounds range from -3.05 to 4.81. CLogP 
values above 5.0 indicate exceedingly low hydrophilicity, and therefore low adsorbtion and 
permeability, and therefore decreased suitability for pharmaceutical use. 
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Table 1.  Small molecule structures, names, and molecular weights. 
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2.2 – Dynamic Light Scattering (DLS) 
Each of the small molecules (Table 1) was allowed to reach room temperature and 
diluted to 50 mM in deionized (DI) water (0.5% DMSO v/v) to a total volume of 800 µL in a 1 mL 
glass cuvette. The cuvettes were then placed into the DLS instrument and read for intervals 
ranging from 10 sec to 2 minutes. DLS spectroscopic data were collected using a NICOMP 380 
ZLS Particle Sizer (Agilent Technologies, Inc., Santa Clara, USA).  The instrument was adjusted 
to measure the optimal light scattering intensity, and the integration time chosen to minimize fit 
error for each sample.  The default autocorrelation function was used to calculate hydrodynamic 
diameter and to estimate particle size. 
 
2.3 – α-Chymotrypsin Enzyme Inhibition Assay 
 A SpectraMax Plus (Molecular Devices, Sunnyvale, CA USA) spectrophotometer (96- or 
384-well microplate reader) was first calibrated with a concentration series of α-chymotrypsin 
(Sigma-Aldrich, St. Louis, MO USA) from 10 ng/mL to 100 µg/mL to determine a fixed enzyme 
concentration. The enzyme concentration was set at 300 ng/mL to give approximately 10–15 
min of linear kinetic optical density unit (OD) output, offering enough time to pipette the 
substrate into all the wells while maintaining a dynamic response to changes in reaction rate.  
The substrate succinyl-AAPF-PNA (Sigma-Aldrich) concentration was fixed at 200 µM in assay 
buffer (100 mM Tris, 20 mM CaCl2, pH 7.8). After the calibration, each small molecule was 
diluted to 1, 2.5, 5, 10, 25, 50, 100, and 250 µM in assay buffer, and incubated with the enzyme 
for 30 min at room temperature.  Finally, the substrate was added to the mixture (final volume of 
50 µL) and the kinetic OD output was recorded for 30 min at a wavelength of 405 nm. 
 To compute the reaction rate, the slope was computed for the linear portion (10-15 min 
as stated above) for the reaction as incubated with each concentration of each inhibitor. A range 
of compound concentrations was employed to verify that inhibition was dose-dependent, and 
not merely an inconsistency for a given compound. No incidence of inconsistencies was 
observed with regard to the dose-dependence of inhibition, though the ability to resolve 
differences in reaction rate consistently declined beyond 10 µM concentrations and lower. To 
simplify display of the results, only data for the highest concentration of inhibitor (250 µM) are 
displayed in Results. 
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2.4 – PC Biosensor Detection of Aggregation 
TiO2-coated, 384-well BINDTM sensor microplates and streptavidin (SA2)-coated 384-
well BINDTM sensor plates were purchased from SRU Biosystems, Inc (Woburn, MA, USA). 
After washing three times with 80 µL distilled ionized water (DI), the TiO2 and streptavidin-
coated 384-well sensor plates were stabilized with a well volume of 15 μL with four different 
buffers: DI, PBS, PBS with 0.1% (v/v) Tween-20, and PBS with 0.1% (v/v) Triton X-100.  The 
analyte concentration used for the PC assay was determined using a series of concentrations of 
the positive control Congo Red. The minimum concentration of CR detected as demonstrating 
aggregation above background levels was 2.5 µM, and saturation was observed at 50 µM. The 
assay appeared to demonstrate decreased sensitivity to aggregation at concentrations lower 
than 50 µM, with a marked decrease in PWV shift at concentrations less than 12.5 µM. In 
deference to this information, the small molecules within our library (including controls biotin and 
CR) were allowed to come to room temperature before being prepared at 50 µM with the buffers 
listed above and 15 µL of each compound was added to the previously equilibrated plate.  The 
PWV shift for each sample was then recorded as a function of time for approximately 5-6 h.  
Following this read step, the PC biosensor plate was washed with the corresponding buffer for 
each well, and the PWV shift was assessed before and after the wash step.  Endpoint readings 
refer to data taken after the wash step. 
 
2.5 – Imaging Small Molecule Aggregation on PC Biosensors 
To verify that PWV shifts observed in the PC Biosensor procedure described above, 
PWV shifts of the small molecules at a concentration of 50 mM were monitored using an 
uncoated PC biosensor microplate with an exposed TiO2 surface and DI as a solvent. After 
washing the uncoated sensor three times with 80 µL DI water, the plate was stabilized with 30 
µL water for approximately 30 min, using the BIND Reader to establish the point of equilibration. 
Images were then constructed using a BIND Scanner (SRU Biosystems, Woburn MA USA) at a 
pixel resolution of 22.3 x 22.3 µm2/pixel after stabilization with DI water (baseline image) and 
again after a 5-6 h aggregation period conducted at RT (aggregation image).  In order to record 
the PWV shift due to aggregation, the registered baseline image was subtracted from the 
aggregation image on a pixel-by-pixel basis, resulting in a final PWV shift image.  To increase 
contrast over the relevant range, the PWV shift depicted in the image was set from -1.40 to 2.10 
nm with a user-selected color map as displayed in the color bar. 
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2.6 – Scanning Electron Microscopy (SEM)  
For further verification that observed results on the BIND sensor correlated with the 
physical aggregation of library compound molecules on the surface of the device, scanning 
electron microscopy was performed on devices incubated with aggregating and nonaggregating 
compounds. Uncoated PC biosensor microplate wells with an exposed TiO2 surface were 
incubated with 3 µL of each small molecule (50 µM in 0.5% DMSO).  The sensors were then 
rinsed with the following sequence of solvents: DI, acetone, DI, isopropyl alcohol, and DI.  
Samples were mounted on an aluminum stage with carbon tape adhesive and sputter coated 
with ~50 Å gold. Images were obtained with a Hitachi SE UHR FE-4800 scanning electron 
microscope (Hitachi, Tokyo, JP) at 15 kV.  Micrographs were recorded at 2 mm under focus at 
varying magnifications. 
 
2.7 – Measuring the Effects of Detergent Using PC Biosensors 
To assess the detergent-mediated inhibition of aggregation, streptavidin-coated 384-well 
sensor plates were temperature-stabilized in 15 µL PBS or PBS + 0.05% Tween-20.   During 
stabilization, small molecules were permitted to come to room temperature before being diluted 
to a concentration of 50 µM in PBS or PBS with 0.05% (v/v) Tween-20. Following dilution, 15 µL 
of each sample was added to the stabilized biosensor and incubated for approximately 5-6 h 
while being and scanned with the BIND Reader. After concluding the incubation period, wells 
were rinsed with 30 µL of the corresponding buffer (PBS or PBS with 0.05% (v/v) Tween-20).  
For establishment of dose-dependence of the observed detergent-mediated inhibition of 
aggregation, PBS was prepared with varying percentages (v/v) of Tween-20: 0.00, 0.01, 0.05, 
0.10, 0.5, 1.00, and 5.00%.  CR was prepared with each buffer to in a dilution series ranging 
from 0.4-50 mM and 15 µL of each dilution was added to the stabilized plate.  The PWV shift 
was then recorded for approximately 5-6 h.  Plates were then rinsed with the corresponding 
buffer and PWV shift was monitored before and after the final wash step.  Endpoint readings 
refer to the PWV values obtained after the wash step. 
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Chapter 3: Results 
	  
3.1 – Motivation and Initial PC Biosensor Results 
As noted in the Introduction, we discovered several compounds that showed binding 
capabilities in excess of expected stoichiometric values in a previous large-scale screening 
experiment [26]. Figure 1 shows data representative of this phenomenon for the dye Congo Red. 
Congo Red has been demonstrated as prone to aggregation, and has also demonstrated an 
ability to inhibit enzyme-catalyzed reactions, presumably through the sequestration mechanism 
summarized above (Introduction). Similar results were obtained for several other documented 
aggregating compounds, including the compounds Rose Bengal [11] and Indigo [12]. The large 
binding signals elicited from these compounds were consistently several times the binding 
signal of a non-aggregating negative control compound (biotin, shown in Figure 1), and would 
occur even upon surfaces that were blocked against biochemical binding. 
 
 
Figure 8.  Kinetic plot of PC biosensor PWV shift as a function of time for a typical aggregating 
compound (Congo Red) and a nonaggregating compound (biotin).  Both molecules were 
introduced in PBS buffer with 0.05% DMSO to separate biosensor microplate wells treated with 
streptavidin.  Aggregation is characterized by a large positive wavelength shift that does not reach a 
stable value, even after >2 h of exposure to the sensor surface.  A buffer wash step (3 times with PBS) 
does not remove the aggregated material from the sensor surface.   
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  Upon closer examination of the binding profiles presented by these aggregators, we 
noted that the signal failed to reach a stable reading, indicating the continued adsorption of 
small molecules to the BIND sensor. As discussed earlier, such an increase is likely attributed 
only to a direct increase in the local refractive index of material within the evanescent field 
region. Because the only compound added to the buffer was Congo Red, we assert that the 
increased signal is due to the deposition of additional Congo Red. Supporting this assertion, 
biotin (an established nonaggregator) results in a Peak Wavelength Value (PWV) shift that is 
several times lower than that displayed by Congo Red. These observations merit consideration 
of the PC biosensor system as a detection system for aggregating small molecules. To pursue 
this study in further detail, we compiled the small molecule library listed above and conducted a 
number of studies on each molecule using screening methodologies currently employed in the 
pharmaceutical screening and biotechnology industries. 
3.2 – Dynamic Light Scattering (DLS) Spectroscopy Results 
 The compounds evaluated in this study are listed in Table 1 (Materials and Methods).  
Library compounds 1-20 were previously uncharacterized as aggregators, while negative 
controls (DMSO, biotin, buffer) and positive controls (Congo Red and a solution of 100nm beads) 
were used for comparison.  Results of the DLS measurements can be seen in Figure 2a.  The 
small molecules showed diameters greater than 100 nm and large standard deviations (for N=3 
independent measurements) in the DLS measurements.  The scattering intensity ranged from 
10 to 500 Hz for compounds tested.  Increased scattering intensity correlates with increased 
hydrodynamic diameter of the particles formed in solution and, therefore, aggregation. The small 
molecules with high scattering intensity (approximately 300 Hz or greater) include compounds 2, 
6, 14, 16, 17, and CR, along with biotin. Low-scattering (approximately 100Hz or fewer) 
molecules include compounds 1, 3, 4, 5, 7, 8, 9, 10, 11, 15, 19, and the 100 nm bead control. 
The efficient scattering presented by biotin is interesting in that it is at odds with its low CLogP 
value and high solubility. This point of contention is evidence of the characteristic unreliability of 
DLS as a high-throughput screening tool. Furthermore, the information gained through DLS 
spectroscopy consistently indicates that biotin is capable of forming aggregates that are 
approximately 300nm in diameter, when this is simply not characteristic of the compound. While 
useful when the critical assumptions of uniformly sized and spatially distributed particles are 
valid, DLS spectroscopy remains a tool of limited utility in the drug screening environment due to 
the significantly variable properties of small molecule candidate libraries. 
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Figure 9: DLS Spectroscopic Analysis for Small Molecule Library. Compounds with greater than 
300 Hz scattering intensity signify increased hydrodynamic diameter of the particles. Such compounds 
include compounds 2, 6, 14, 16, 17, and CR. Compounds with reduced scattering intensity (fewer than 
100Hz) include compounds 1, 3, 4, 5, 7, 8, 9, 10, 11, 15, and 19, in addition to the 100nm bead 
control. (b) DLS fit error for the size measurements obtained in (a).  Note that large standard 
deviations in diameter measurements do not necessarily correlate with large fit errors, indicating that 
other factors may be responsible for these inconsistencies. 
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Further examination of the DLS data gives a measure of insight as to the unreliability of 
DLS spectroscopy for this application.  The DLS instrument provided a fit error value for each 
compound (Figure 2b), and compounds with high scattering intensity showed low fit error, and 9 
of the low-intensity compounds showed large fit error relative to the 100nm bead control sample.  
Additionally, while the 100nm bead positive control gave results consistent for 100nm diameter 
particles, the results for DMSO only and biotin (nonaggregator control) were within the same 
range. Finally, the fit error for DMSO and for the vehicle control sample are significantly greater 
than the 100 nm bead control, lending a further decrease in credibility to the DLS assay. These 
consistent false positive results are indicative of the fact DLS may be limited in the detection of 
the types and sizes of aggregates formed by drug-like compounds.  
 
3.3 – α-Chymotrypsin Assay Analysis 
Inhibition of α-chymotrypsin was quantified in terms of reduction of the base reaction 
rate. This reaction rate was determined through the calculation of the slope of the linear portion 
of data generated from the increase in absorbance at a wavelength of 405 nm over time caused 
by cleavage of succinyl-AAPF-PNA by α-chymotrypsin. As the reaction continues, absorption at 
405 nm increases due to the increased formation of the colorimetric product, paranitrophenolate. 
Reading entire 384-well multiwell plates allowed multiplexing this assay, although the use of 
several plates was required to run all combinations of drug candidate concentrations in parallel 
with uninhibited reactions.  The linear portion of the graph (0 - 15 min) was used for slope 
calculation and comparison to potential inhibition or activation by our compound library. After 
calculating the reaction rate for each concentration of compound, the resulting rates were 
normalized to the rate established in the absence of small drug-like molecules (DMSO/vehicle 
control) to ease comparison. This assay was repeated three times with similar results, displayed 
in Figure 10. DMSO was run as a vehicle control, while CR and biotin were used as positive and 
negative controls for inhibition, respectively. To establish dose-dependence for the inhibitory or 
activating activity displayed by each compound, this experiment was run with a range of 
concentrations for each of the drug-like compounds in the small molecule library. 
Concentrations ranged from 1µM to 250µM, and are specifically listed in Materials and Methods. 
To highlight the reaction-altering properties of the compound library in this assay, the highest 
concentrations (250 µM) of compounds 1-20, CR, and biotin are depicted in Figure 3.  All 
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percent activity data were normalized to the slope of the line generated from DMSO treated α-
chymotrypsin and substrate.  Note that several apparent increases in activity occur with 
compounds previously described as promiscuous inhibitors (CR).  This discrepancy may be 
attributed either to the possibility that the compounds enjoy some spectral overlap with the 
reaction product, p-nitrophenolate, at the wavelength measured by the spectrometer. This 
highlights a potential weakness of enzyme inhibition assays in general. To rule out the 
possibility that spectral overlap is responsible for perceived increases in reaction rate, it would 
be necessary to repeat the assay several times with differing enzymatic reactions and differently 
colored substrates and reaction products. This would result in substantially increased costs as 
well as decreased reliability, as sourcing and establishing the efficacy of each batch of enzyme 
are costly enterprises, in terms of both time and physical resources. 
 
Figure 10: α-Chymotrypsin Inhibition Assay. Each molecule in the screening library was incubated 
in context with an α-chymotrypsin reaction with the colorimetric substrate succinyl-AAPF-PNA. 
Inhibitory or activating activity can be observed, as the results were normalized to unaltered 
progression of the reaction with the vehicle control, DMSO. 
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3.4 – Aggregation Detection on PC Biosensors 
 PC biosensor-based assays introduced a reduction in assay complexity as compared to 
the enzyme inhibition studies documented above. As the PC biosensor results respond directly 
to the increased mass of an aggregating compound near the sensor surface rather than on an 
indirect property, meaningful results can be obtained simply from incubating the compounds on 
the sensors at an optimal concentration. To determine the concentration optimal for establishing 
the presence or absence of aggregating activity, the PC biosensor assay was run at a series of 
concentrations from 1 µM to 250 µM with the compound Congo Red, a known promiscuous 
inhibitor. While detection of a binding profile similar to that shown in Figure 7 was determined for 
concentrations as low as 12.5 µM, the PC biosensor assay possessed decreased sensitivity at 
concentrations less than 50 µM. As a result, screening experiments for all molecules took place 
at a concentration of 50 µM to maximize sensitivity to aggregation while minimizing compound 
use. The PWV shifts recorded for each compound in the small molecule library are shown in 
Figure 11. Congo Red was used as a positive control, while biotin, buffer, and the vehicle 
control (DMSO) serve as negative controls for aggregation. Relative to the negative control 
samples, the PC biosensor detection instrument recorded an increase in the PWV for several of 
the compounds, including compounds 6, 8, 9, 10, 11, 12, 13, 15, 17, 19, and 20. Although the 
sensor surface was washed rigorously with buffer 3 times the wavelength shift remained, 
indicative of a binding interaction. These results were interpreted as evidence of prolonged 
nonspecific attachment of material to the sensor surface as a direct result of compound 
aggregation. 
 Several compounds incubated on the PC biosensors displayed little to no PWV shift, 
indicating that there was no bias as to where the molecules settled or bound after prolonged 
incubation. Though the compounds were added under the same conditions as those highlighted 
above, compounds 1, 2, 3, 4, 5, 7, 14, 16, and 18 showed little to no binding activity. This 
indicates that the compounds likely remained in solution, as no evidence of aggregation could 
be documented via PWV shift. The results for these compounds were similar to those for the 
three negative control samples. Samples were run in triplicate, and error bars represent one 
standard deviation above and below the mean. As shown in Figure 11, PC biosensor results 
were observed to be relatively consistent among replicates. 
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3.5 – Aggregation Imaging on PC Biosensors 
Compounds 1-20 provided a trial set for the ability of PC biosensors to detect 
aggregators. To verify that these readings were the result of consistent and reproducible shifts 
in PWV, we confirmed results for a subset of molecules chosen to exemplify aggregating and 
nonaggregating activity as observed on the PC biosensor surface. Specifically, based on the PC 
biosensor data in Figure 11, compounds 1 and 2 were selected for further study as non-
aggregators, while compounds 8 and 19 were selected as aggregating small molecules. After 
Figure 11: PC Biosensor-Based Detection of Aggregation. Each molecule in the screening library 
was incubated at a concentration of 50 µM in PBS in a PC Biosensor microplate for a period of 6 h at 
RT. After the incubation period, all wells were rinsed three times with 80 µL DI water, after which the 
endpoint read displayed above was taken. A DMSO vehicle control was run to verify that PWV shifts 
were not a product of bulk refractive index shifts. 
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washing and temperature stabilization in PBS, PC biosensors were incubated with each of these 
compounds at the screening concentration of 50 µM in PBS for a period of approximately 6 h. 
Using the BIND imaging instrument, pre- and post-incubation scans were obtained for 
comparison and calculation of a PWV shift image, each displaying peak wavelength value as a 
function of position over the entire PC biosensor microplate. Using image registration, the pre-
incubation PWV image was subtracted from the post-incubation PWV image, and the results 
were recorded as displayed in Figure 12 below. The PWV shift image shows a large PWV shift 
for the two putative aggregating small molecules (8, 19) while the two reference compounds (1, 
2) and the vehicle control (DMSO) showed no appreciable binding signal.  The PWV shifts 
recorded by the imaging detection instrument are of magnitudes consistent with those measured 
using the optical fiber probe detection instrument (approximately 1.0 and 1.2 nm for compounds 
8 and 19, respectively).  The PC biosensor imaging data show that aggregation for compounds 
8 and 19 appears to occur uniformly across the biosensor surface at the bottom of the well, and 
not in sparsely isolated clusters. This would seem to indicate that aggregation formation occurs 
at sizes consistent with the order established during the DLS assay, well under 1 µm in diameter, 
and so sufficiently below the pixel resolution of the BIND imaging instrument (22.3µm x 
22.3µm/pixel). 
Upon closer inspection of the PC biosensor imaging data, there appears to be a 
prevalence of PWV shift on the outer boundary of each well. This may be a reflection of 
increased deposition on the plastic sidewalls of the well plate. An alternative explanation would 
be preferential deposition at locations containing the UV-curable polymer used to secure the 
biosensor to the well plate. Because the polymer is pressed between a bottomless well plate 
and the PC biosensor before being cured, excess polymer can leak slightly into the well during 
fabrication. Such a surface may provide additional incentive for compounds to adsorb at these 
locations. The consistent increases in PWV shift at the bottom right corner of each well are due 
to mechanical degradation of the sensor due to rough handling of the pipette tip used for 
aspiration. Because the illumination spot of the BIND Reader remains within the center of each 
well, it is unlikely that effects of either of these observed mechanical defects could be observed 
in the PC biosensor screening data discussed earlier. 
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3.6 – Confirmation of Small Molecule Aggregation on PC Biosensors via SEM 
 To provide further verification that the results observed on PC biosensors were indicative 
of physical aggregation of small molecules, scanning electron microscopy was used to 
qualitatively demonstrate the presence of compound aggregates as they occur on the 
biosensors. The small molecules described in Figure 12 were incubated on PC biosensors, 
using 3 µL of each compound at 50 µM, including DMSO as a negative control. Experiments 
using sensor surfaces treated with the vehicle (DMSO) and compounds 1 and 2 resulted in a 
clean grating surface image when examined by SEM, in which no particulates or other deposits 
could be observed (Figures 13a, 13b, 13c) across the sensor surface.   
Figure 12. PWV shift images of selected individual 384-well microplate wells, gathered with the 
PC imaging detection instrument, demonstrating uniformly high levels of aggregation distributed 
across the biosensor surface for several compounds ((d) 8, (e) 19) and lack of wavelength shift for two 
non-aggregator compounds ((b) 1, (c) 2) and (a) DMSO reference solution.   
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Figure 13.  SEM images of (a) DMSO, compounds (b) 1, (c) 2, (d) 8, and (e) 19.  The two 
aggregators (8, 19) showed gel-like substance attached on the sensor surface, while such substance 
could not be located on the non-aggregator and DMSO surfaces.  A kinetic plot containing all five 
molecules shows that (f) the aggregators slowly increased to a high PWV shift signal even after a 
rigorous washing step. 
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In contrast, the sensors incubated with 50 µM concentrations of compounds 8 and 9 
(that had registered a positive binding signal in the PC aggregation assay) exhibit a gel-like 
substance attached to the surface when imaged by SEM (Figures 13d, 13e).  The material is 
observed to attach to the sensor in irregularly-shaped clusters that fill in the grating grooves and 
extend for several grating periods (a single grating period is 550 nm).  Although isolated clusters 
are shown in Figure 6, clusters could be found distributed uniformly across the entire sensor as 
suggested by the PC biosensor imaging measurements shown in Figure 12.  The material has 
the appearance of a thick film with a highly variable shape capable of conforming to the grating 
period and filling gaps in the diffraction grating surface. These films are characteristic of the 
shapes of small molecule aggregators and promiscuous inhibitors reported by Shoichet et al.  
[11]. In no case were aggregate formations in the shape of round or spherical objects observed. 
For a direct comparison of the long-term aggregation present with compounds 8 and 19 
and the non-aggregating compounds 1 and 2, the kinetic data from the PC biosensor screen are 
displayed in Figure 13f. Aggregating compounds display a kinetic profile similar to that of Congo 
Red, while the nonaggregating compounds and vehicle control display little in the way of binding 
activity (as displayed by PWV shift), and reach stable values with relative ease. The aggregating 
compounds, by contrast, enjoy a steep initial increase in PWV shift, followed by a gradual 
increase, despite hours of incubation given to achieve stabilization. As with Congo Red, this 
continued lack of stability likely stems from continued deposition of aggregating small molecules 
on the sensor surface and within the evanescent field region, indicative that these molecules 
possess non-specific binding activity. 
 
3.7 – Detergent-based inhibition of small molecule aggregation 
 Previous studies have reported that small molecule aggregation-induced inhibition of 
aggregation can be ameliorated through the use of detergent compounds such as Tween-20 
and Triton X-100. To verify that PC biosensor-based detection sensitivity is capable of detecting 
detergent-induced restriction of small molecule aggregation, the PC biosensor screening 
experiment was repeated with and without the use of Tween-20. Each small molecule was 
allowed to progress to room temperature before diluting to 50 µM in PBS with and without 
0.05% (v/v) Tween-20 and adding to a temperature-stabilized PC biosensor. The results are 
documented in Figure 14a, and show universally decreased response among aggregators as 
detected using the PC biosensor assay (Figure 11). Peculiarly, samples that do not show 
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aggregation-like activity in the PC biosensor assay exhibit a slight increase in PWV shift with the 
addition of detergent. This would seem at odds with the mechanism of the detergent, which 
relies on micelle formation to sequester individual particles from interacting with one another. 
One possible explanation for this observation could be that the negative charge imposed by the 
detergent molecules results in a slightly increased incentive for small molecule binding of the 
sensor surface. This slight increase, however, is much smaller in magnitude than the decreased 
PWV shift observed with documented and putative aggregating small molecules. 
 To verify that these reductions in aggregation were consistently dose-dependent, the 
most prominent example of aggregation (and aggregation reduction) was chosen. Congo red 
was shown the experience a 50% decrease in the observed PWV shift value in the presence of 
only 0.05% Tween-20, so it was established as the compound for studying dose-dependent 
reduction of aggregation through the use of detergents. As displayed in Figure 14b, 0.00%, 
0.01%, 0.05%, 0.10%, 0.50%, 1.00%, and 5.00% (v/v) Tween-20 in PBS were incubated with 
concentrations of Congo Red ranging from 0.1 µM to 50 µM for a period of 5 h in PC biosensor 
microplates. The microplates were then rinsed three times with 30 mL DI water before obtaining 
an endpoint reading for the assay. Results were recorded as displayed in Figure 14b. The 
logarithmically increasing concentrations of detergent seem to have a roughly linear affect on 
binding affinity, with negligible reductions in signal occurring at all Congo Red concentrations 
with Tween-20 concentrations below 0.05% (v/v). Notably, the difference between 0.00% and 
0.01% (v/v) is greatly reduced in comparison to the reduction observed for subsequent 
detergent increases. The reduction in PWV shift resulting from the next concentration (0.05% 
(v/v) is approximately 60% across the range of concentrations of Congo Red. 
 These results provide further confirmation that PC biosensors can be used to confirm the 
presence of aggregating small molecules, and that they can be used to investigate which factors 
might be responsible for reversing or inhibiting undesired aggregation. Finally, although the 
binding curves remain relatively consistent, there are some areas of overlap at the lower analyte 
concentrations. Because sensitivity to analyte binding has been noted as limited at 
concentrations below 12.5 mM, it is likely that PC biosensor assessment of aggregation below 
this concentration is currently unreliable. The use of higher precision liquid handling systems 
may allow further decreases in achievable detection limits in the future, but screening 
concentrations should remain at 50 µM until such inconsistencies can be resolved. 
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Figure 14: Detergent-based inhibition of small molecule aggregation (a) PC biosensor 
aggregation measurements showing the effect of 0.05% Tween-20 added to the buffer as a method for 
reducing compound aggregation.  (b) A plot of PC biosensor aggregation signal as a function of 
aggregator (Congo Red) concentration for Tween-20 percentages of 0-5%, demonstrating that as 
detergent percentage increases, the aggregation signal decreases, and that aggregation is also 
dependent upon the concentration of the compound.   
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Chapter 4: Discussion 
	  
 The goal of the work presented in this paper was to present PC biosensor assays as a 
direct means for detecting aggregation of small molecules in the context of pharmaceutical 
screening assays. In liquid media exposed to the PC biosensors, aggregating compounds 
appear to result in deposition of material upon the sensor surface; this manifests itself as a 
substantial increase in the PWV, simplifying the process of these problematic aggregating 
compounds.  To demonstrate the potential utility of this method for pre-screening aggregators 
from a compound library, the PC biosensor aggregation method was tested for agreement 
against other commonly used techniques.  Additional validation studies included the verification 
of commonly used strategies for reducing aggregation, and namely whether the addition of 
detergent to the compound buffer, would result in modulation of the aggregation signal 
measured by the biosensor, and to demonstrate characterization of the concentration 
dependence of compound aggregation. 
 Of the 22 compounds tested, the PC biosensor assay showed limited evidence of 
aggregation for several compounds (1, 2, 3, 4, 5, 7, 14, 16, and 18) in addition to three negative 
controls (DMSO, biotin, and buffer).  Several compounds resulted in measured aggregation with 
the PC assay (6, 8, 9, 10, 11, 12, 13, 15, 17, 19, and 20), in addition to the positive control (CR) 
(Figure 11). Despite the elevated concentrations used in the PC detection and enzymatic 
inhibition assays, only a small fraction of the compounds (1, 2, and 7) showed evidence of 
precipitation. It is worth noting that the PC biosensor results show little correlation with 
estimated hydrophilicity/solubility, as both CR and biotin possess hydrophilic CLogP values (-
3.05 and -1.33, respectively). The test compounds had a broad distribution of hydrophobic 
CLogP values (0.99 to 4.81), with neither more nor less hydrophilic molecules showing 
preferential detection of aggregation. Furthermore, the material deposited upon the sensor 
surface attributed to aggregation remained even after rigorous washes with buffer. These 
observations suggest that the aggregation was not the result of a precipitate and that the 
measured signals were not caused by such spurious effects as changes in the bulk refractive 
index of the small molecule buffer.  Additionally, the lack of bias toward a particular class of 
molecules regarding molecular weight, charge, functional group, or hydrophilicity presents the 
PC biosensor detection assay as an objective method for detection of aggregation. By contrast, 
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precipitating and colored compounds can cause significant concern for the DLS spectroscopy 
assay as well as enzyme inhibition assays, respectively. 
Although DLS is often used in the pharmaceutical screening industry to measure the size 
of dispersed particles in solution, dynamic light scattering was not useful for characterizing the 
aggregations of the compounds in the panel studied in this work. Multiple readings showed 
disparities among the results for each small molecule, hampering data collection and 
compromising its validity.  Particle diameter measurements of all 22 samples were obtained 
(including the negative controls), but with typically large standard deviations (Figure 2) and 
particle size readings of ~100 nm particle diameter for the negative controls (DMSO, biotin, and 
buffer) severely limited the utility of the data obtained.  DLS measurements of scattering 
intensity can be used as a means for estimating particle diameter based upon Mie-theory 
calculations that assume an even distribution of uniform spherical particles [14, 15].  However, if 
the particles do not fit this model, the results can be inconsistent, as shown by our results.  We 
note that most of the compounds that register high scattering intensity were also aggregators 
identified by the PC biosensor. The DLS measurements also could not be performed in a high 
throughput fashion, as the detection instrument could only measure one sample at a time with 
each measurement taking 30 sec – 2 min. 
 Enzyme-based assays remain another commonly used HTS tool for promiscuous 
inhibitors. The α-chymotrypsin-based enzyme inhibition assay uses a colorimetric reaction to 
measure the reaction rate for each compound as a function of concentration, requiring a 
concentration series for each molecule under study and a calibration standard for comparison.  
Several compounds were identified as promiscuous inhibitors identified using this method (6, 10, 
12, 14).   These results are mostly consistent with those obtained with the PC biosensor 
detection method.  Colored compounds and those subject to precipitation, including several of 
the small molecules evaluated here, however, can affect absorbance measurements as a result 
of physical characteristics unrelated to their propensity for aggregation.  As a result, enzymatic 
inhibition assays can identify potential promiscuous inhibitors that inhibit the particular enzyme-
substrate interaction used, but they remain incapable of identifying all the aggregators because 
not all aggregating compounds are promiscuous inhibitors[16].  Therefore, this detection method 
limits reliability and throughput in achieving the goal of accurately identifying possible 
aggregators within a small molecule library.  
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 To verify that aggregation observed on the PC biosensor as interpreted from increased 
PWV shift was indeed the result of physical adsorption of small molecules, physical inspection 
was performed using SEM to examine the PC biosensor surface.  Two aggregators (8, 19), two 
non-aggregators (1, 2), and one reference sample (DMSO) were examined and compared using 
SEM.  Surprisingly, islands of thick films were found on the surface of the PC sensors exposed 
to the potential aggregators (Figure 13) and it is probable that these deposits caused the large 
measured PWV shifts.  The observed deposits were absent from sensors exposed to non-
aggregators, as well as from the sensors exposed the vehicle control (DMSO). The same 
samples were scanned using the PC imaging instrument, showing that these deposits are 
uniformly present over the entire sensor surface area and that the deposits cause a large 
positive in shift in PWV (Figure 12).  These observations are again consistent with large scale 
deposition of aggregating small molecules on the sensor surface through a mechanism that 
differs from simple precipitation, and that agrees with previously documentation concerning 
aggregating small molecules. 
 As stated previously, the use of detergent has been reported as a means to reduce the 
compound aggregation, and a quantitative method for measuring aggregation should ideally be 
able to measure the effects of detergent and the effects of the compound concentration.  Such 
measurements may prove useful in the identification of marginal compounds, for which 
aggregation effects may be avoided under the correct conditions. Additionally, such studies are 
warranted for borderline compounds in order to learn more about the nature of their aggregation 
and possible mechanisms or molecular alterations by which such aggregation may be restricted.  
To this end, we conducted an experiment to confirm that the PC biosensor can be used to 
observe the effects of detergent on possible aggregators, as well as for related studies in the 
future. For these experiments, Tween-20 (0.05% v/v) was mixed with the compounds in PBS 
and a decrease in the aggregation signal occurred for most of the small molecules, including all 
of the significant aggregating compounds.  Congo Red, the most prolific aggregator, showed the 
greatest reduction (60%) in nonspecific binding in response to the addition of varying 
concentrations of detergent. This information was used to plot a PWV shift curve as a function of 
concentration in respect to Tween-20 percentage (Figure 14).  Decreased PWV shift in 
response to increased detergent concentration supports the hypothesis that PWV shift as 
described here is proportional to a given small moleculeʼs propensity for aggregation. 
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Chapter 5: Conclusion 
	  
 In this work, the use of PC optical biosensors in a 384-well microplate format is 
established as a means for identification and quantitative characterization of small molecule 
aggregation effects.  The PC biosensor measures the optical density of material deposited upon 
its surface, and therefore directly measures aggregating material that forms on the sensor 
surface from the liquid media within each well of the biosensor microplate.  A small panel of 
chemical compounds, negative controls, and positive controls were characterized by the PC 
biosensor method, DLS, a chymotrypsin enzyme assay, and direct visual observation with an 
electron microscope.  SEM observation showed that aggregation deposits on the sensor were 
found to form clusters of dense material with irregular shapes that are not easily fit with standard 
spherical particle models used in DLS, resulting in large fit errors and standard deviations 
obtained by that method.  The aggregates were found to persistently attach uniformly to the 
entire sensor surface area and were not removable by vigorous washing.  Aggregation detection 
with the PC biosensor assay agreed with measurements gathered by the chymotrypsin assay, 
but the PC biosensor method proved to be more amenable to higher measurement throughput 
and a simpler procedure.  The ability to not only identify aggregators but to also quantify the 
degree of aggregation was demonstrated using various concentrations of detergent and 
compound to modulate the aggregation effect. Importantly, the PC detection assays used in this 
study showed no bias with regard to molecular weight, composition, hydrophilicity, color, or 
solubility, indicating that the assay is objective and robust in the face of many variable 
encountered in high-throughput screening. 
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